Is $340 the next stop??Maybe we touch $342 as early as this week. It looks like it has the momentum to get there. All speculation so don’t get a bent out of shape. This is simply for fun. What are your thoughts??
UNH trade ideas
UNH is a Great Opportunity Following Panic Sell-Off UNH remains a solid business with a great potential upside. The recent drop was driven by softer financials, CEO resignation, and a DOJ probe—more fear than fundamentals.
Core operations are stable. Valuation is now attractive, making this a solid entry point for patient investors.
Many argue that UNH is just an insurance business, not a tech company. They are wrong. UNH holds a massive amount of healthcare data that can be leveraged for insights, efficiency, and innovation. This data is not just an asset—it is a moat that few competitors can replicate.
The recent insider buying is a green flag ! a signal for investors that there are no skelatons in the closet
On the chart, increasing green volume supports bullish sentiment. The 10-day EMA has crossed above the 20-day EMA on the hourly timeframe, indicating short-term upward momentum. Additionally, the MACD is turning positive indicating less fear and more greed!, and RSI is trending higher—both pointing to strengthening buying pressure.
Life Time Opportunity Trade Setup NYSE:UNH
Entry Price: $280 (at market open)
Profit Target: $400
Stop Loss: $250
Risk-Reward Ratio: 4.3:1
Position Size: 1% of portfolio
Why Bullish?
UNH is trading near a 5-year low ($248.88) after a -50% drop in a month, driven by a DOJ Medicare fraud probe and CEO change. Despite the noise, analysts are bullish with 55 Buy ratings and a $445-$460 target, pointing to undervaluation (forward P/E ~10x). Institutional buying (Viking Global +12.5% stake) and a low VIX (17.83) support a potential rebound.
Key Catalysts
Technicals: Near 52-week low, RSI oversold, potential reversal.
Fundamentals: $400B revenue, 15% EPS growth projected long-term.
News: DOJ probe and suspended 2025 guidance weigh, but analysts see overreaction.
Macro: VIX at 17.83 (stable), 10-year yields at 4.424% (headwind).
Risks
Ongoing DOJ investigation could escalate.
Rising medical costs and volatile sentiment.
Further downside if support at $250 breaks.
Chart Notes
UNH testing major support at $250-$270.
Volume spikes on selling, but capitulation may signal a bottom.
Watch for a break above $300 to confirm bullish momentum.
Keep your long term vision
Follow for the Best AI generated Signals on the market
Ash.
UNH can retrace the fib and come back to the lowSee trading is all about risk and probability.
There is news flowing left and right about insiders buying UNH for the dip, a director bought about $1m single handedly.
But remember, DOJ is serious about the Medicare Fraud Probe.
I believe since there is a huge, huge downfall from April 16, 2025... there will definitely be a retracement, but not till .5 or .618, imo.
So after retracement to 381 range, it may again fall down to 250 low ( as rapid downfall, suggests retracement to only 0.38 range, from my personal experience).
Huge Volume spike is also seen stating a lot of people are being involved in this stock. Some may try to get rid off it as soon as possible, some might speculate the comeback of UNH to 594 normal range.
$UNH still looks very uglyI'm still bearish on NYSE:UNH until 335-340 area gets taken out. The chart is so ugly. We've seen many "too big to fail" companies die out eventually. Will NYSE:UNH survive all this bad publicity? Insider action, options flow suggest this isn't going "parabolic" anytime soon lol sorry bulls
The technicals just don't align YET to the upside.
This is still so far from major moving averages on the higher time frames... the volume dried out after those huge moves and consumers hate them right now lol.. this is feeling like NYSE:GME apes versus wall street bullies. Except its NYSE:UNH versus the insured consumers finance.yahoo.com
20EMA on the daily = 342 still not even close
Also FYI - NYSE:UNH is not the type of stock that goes parabolic, nothing sexy on the options flow either
Below 290, I've got 275, 260, and 210 gap down. Good luck bulls and bears
Near-Term Rebound or Continued Weakness Ahead?
Targets:
- T1 = $301.50
- T2 = $308.00
Stop Levels:
- S1 = $287.50
- S2 = $283.00
**Wisdom of Professional Traders:**
This analysis synthesizes insights from thousands of professional traders and market experts, leveraging collective intelligence to identify high-probability trade setups. The wisdom of crowds principle suggests that aggregated market perspectives from experienced professionals often outperform individual forecasts, reducing cognitive biases and highlighting consensus opportunities in UnitedHealth Group.
**Key Insights:**
UnitedHealth Group (UNH) finds itself at a technical and strategic inflection point, presenting opportunities for near-term positioning. This healthcare giant has struggled with recent sector-wide headwinds, including concerns around reimbursement rates and broader market volatility. The $295 level represents a significant area of consolidation, with resistance looming around $300-$308. Analysts emphasize close monitoring of volume spikes as they could signal either bullish conviction or continuation of recent weakness.
A deeper dive into sector fundamentals indicates that defensive healthcare stocks may benefit from a potential market rotation, particularly if the broader market encounters volatility. UnitedHealth Group's dominating position within managed healthcare leaves it well-positioned long-term, but short-term sentiment has weighed heavily, leading to over 10% declines in the last month.
**Recent Performance:**
Shares of UNH have declined in tandem with broader healthcare indices, lagging behind key benchmark ETFs like XLV. Over the last month, the stock dropped sharply from the $330 range and now faces strong technical resistance near $300. Recent market weakness reflects unfavorable investor sentiment as well as concerns over federal investigations and leadership uncertainty.
Expert Analysis:
From a technical perspective, traders point to the $287-$290 range as a critical support zone. A bounce off these levels could lead to short-term retracement opportunities targeting $301 and $308. Below $287, the stock could face further downside to the $275 level. Expert traders recommend cautious LONG positions, highlighting the importance of clearly defined stop-loss orders to navigate the current turbulent environment. Sentiment remains mixed due to ongoing investigations into Medicare billing practices.
News Impact:
Recent headlines around a federal probe into UnitedHealth’s Medicare business and the resignation of its CEO have created a cloud of uncertainty around the stock. This type of news-driven sentiment has weighed heavily on the share price and could limit near-term upside unless key questions around corporate governance and regulatory compliance are addressed.
Trading Recommendation:
Considering its current technical levels and mixed sentiment, we adopt a cautiously bullish stance on UNH. Traders may consider entering LONG positions near $295 with a stop-loss below $287 to protect initial capital. Upside targets of $301 and $308 are realistic in the short term, but disciplined risk management is critical given heightened volatility within the healthcare sector.
UnitedHealth Group:A Healthcare Giant Undervalued Amid AI GrowthUnitedHealth Group NYSE:UNH , the largest health insurer in the U.S., has faced turbulence, with its stock dropping from $600 to $295.57-a 53.1% decline since its peak. Despite challenges, UNH presents a compelling value play, leveraging AI to drive growth and efficiency. Here’s why investors should consider this healthcare titan at its current price.
A Rough Road: DOJ Probe and Public Backlash
UNH’s recent struggles stem from two major events. In December 2024, Brian Thompson, CEO of its insurance division, passed away in New York City, sparking criticism of UNH and the U.S. health insurance system. Following this, the U.S. Department of Justice launched an investigation in early 2025, alleging potential Medicare fraud through inflated treatment costs in UNH’s Medicare Advantage business. These events have shaved over $225 billion off UNH’s market cap since November 2024, bringing it to $264.80 billion.
However, such challenges are not something new for large corporations. Historically, giants like UNH settle regulatory issues with fines rather than severe penalties. Warren Buffett’s Berkshire Hathaway NYSE:BRK.A remains a major shareholder, signaling confidence in UNH’s governance and long-term stability.
Financial Strength and Undervaluation
Despite the selloff, UNH’s fundamentals remain robust. The stock trades at a P/E ratio of 11.4x, down from 17 earlier in May 2025, reflecting the price drop. Analysts project 2025 EPS at $30, implying a forward P/E of 9.7-a bargain for a company of UNH’s stature. Its 3.1% dividend yield, bolstered by 15 years of consecutive increases, adds income appeal. With a market-leading position, serving ~150 million individuals globally, and strong cash flows, UNH is well-positioned to weather short-term storms.
AI: A Catalyst for Growth
UNH is harnessing AI to transform its operations. Handling ~5 billion claims annually, the company uses AI to automate claims processing, reducing costs and boosting margins. AI also analyzes patient data to assist doctors with treatment decisions, enhancing care quality. Beyond internal efficiency, UNH aims to monetize this technology by selling AI solutions to other insurers and medical institutions, opening a new revenue stream. Such moves and steps in this way aligns with UNH’s broader strategy of leveraging technology to modernize healthcare, as seen in its Optum division’s focus on data analytics and pharmacy services.
Investment Case: Buy on Weakness?
At $295.57, UNH is undervalued, offering a margin of safety for long-term investors. Its forward P/E of 9.7 and 3.1% dividend yield make it attractive, while AI-driven growth positions it for future gains. Risks remain, as usual-regulatory fines and market volatility could pressure the stock-but healthcare’s resilience and UNH’s leadership mitigate these concerns. Investors seeking a stable, growth-oriented play in a turbulent market may find UNH as a pretty well buy case.
UNH - can price recover next week?I bought Call Option at strike 250 / Expiration May-30-2025
Again, not a typical trade. Just paid pennys to take possible huge RRR advantage.
I also bought Put Bear Spread in the last trade: see
This can be a a huge profit if we see big volatility in the next week. Up or down. Does not matter.
IT WILL COLLAPSEIt will all collapse. UNH was down -25% and -18% on the day like a week ago. The thing will collapse and so will the american stock market.
UNH can start DCA investment Strategy. 18 May 2025
UnitedHealth Group (UNH) – Oversold & Attracting Insider Confidence
UNH has recently drawn attention after its stock price dropped over 50% since mid-April 2025. Putting aside the fundamental and media noise, the technical analysis shows that the stock is heavily oversold.
Last Friday, the stock rebounded over 6%, possibly driven by a strong show of confidence from insiders. Newly reinstated CEO Stephen Hemsley purchased approximately $25 million worth of UNH shares (86,700 shares at an average of $288.18). CFO John Rex also acquired $5 million, with directors Timothy Flynn and Kristen Gil making significant purchases as well.
From a price action standpoint, the current level appears attractive for a Dollar-Cost Averaging (DCA) approach. However, I'm personally eyeing a potential deeper discount entry zone between $200–$220, which would offer an even more compelling long-term risk-reward setup.
Strategy: Start small with DCA at current levels, but be patient for deeper dips for larger entries.
UnitedHealth Group Stock Chart Fibonacci Analysis 051625Trading Idea
1) Find a FIBO slingshot
2) Check FIBO 61.80% level
3) Entry Point > 287/61.80%
Chart time frame: D
A) 15 min(1W-3M)
B) 1 hr(3M-6M)
C) 4 hr(6M-1year)
D) 1 day(1-3years)
Stock progress: A
A) Keep rising over 61.80% resistance
B) 61.80% resistance
C) 61.80% support
D) Hit the bottom
E) Hit the top
Stocks rise as they rise from support and fall from resistance. Our goal is to find a low support point and enter. It can be referred to as buying at the pullback point. The pullback point can be found with a Fibonacci extension of 61.80%. This is a step to find entry level. 1) Find a triangle (Fibonacci Speed Fan Line) that connects the high (resistance) and low (support) points of the stock in progress, where it is continuously expressed as a Slingshot, 2) and create a Fibonacci extension level for the first rising wave from the start point of slingshot pattern.
When the current price goes over 61.80% level , that can be a good entry point, especially if the SMA 100 and 200 curves are gathered together at 61.80%, it is a very good entry point.
As a great help, tradingview provides these Fibonacci speed fan lines and extension levels with ease. So if you use the Fibonacci fan line, the extension level, and the SMA 100/200 curve well, you can find an entry point for the stock market. At least you have to enter at this low point to avoid trading failure, and if you are skilled at entering this low point, with fibonacci6180 technique, your reading skill to chart will be greatly improved.
If you want to do day trading, please set the time frame to 5 minutes or 15 minutes, and you will see many of the low point of rising stocks.
If want to prefer long term range trading, you can set the time frame to 1 hr or 1 day.
UnitedHealth Group | UNH | Long at $323.00UnitedHealth Group NYSE:UNH currently has a P/E near 15x, steady rising revenue (2024 = $400+ billion), EPS of 6.24x, dividend of 2.2%, and earnings are forecast to grow by 10.8% per year. The stock, however, has plummeted recently due to negative news, rising healthcare costs, CEO changes, and suspension of 2025 outlook. Every company has bumps, but I view solid companies like NYSE:UNH as pure opportunities for long-term investment - especially with America's aging population.
From a technical analysis perspective, the stock price has entered my "crash" simple moving average zone (which currently extends down near $307.00). Personally, this is the zone I am starting a position due to the odds of a future bounce from here. However, I am very aware that there is an open price gap near $265.00 that may get filled this year or early next. I could see a bounce in my crash zone to bring in the bulls and then a drop to that level to heighten the fear. That is another area I plan to grab more shares and build a strong position. But, in case it doesn't extend that low, I have started a position at $223.00, with future investments near $307.00 and below. I doubt this will be a quick turnaround stock - patience is where money is made.
Targets (into 2028):
$375.00
$475.00
$580.00
What price action says about UNHThe recent +55% drop in UNH represents a major breakdown from its long-term price structure. Historically, recoveries in this stock have been slow and gradual rather than sharp rebounds. There is a critical support zone between $190 and $155. While the damage to the stock is significant, this support zone provides a logical area where a patient, steady recovery could develop over time.
- UNH Down 38.2%—Are Buyers Ready to Step In?- "Healthcare Stocks at Higher Timeframe Support (Golden Ratio) —Bounce Incoming?"
Key Reasons for UNH’s Stock Decline
✅ CEO Resignation → Andrew Witty stepped down for personal reasons, and former CEO Stephen Hemsley returned to stabilize the company.
✅ Suspended 2025 Outlook → UNH withdrew its financial guidance, citing higher-than-expected medical costs from new Medicare Advantage members.
✅ Regulatory Scrutiny → The DOJ is investigating UNH for possible Medicare fraud, adding uncertainty.
✅ Cybersecurity Breach → A massive data breach at its subsidiary Change Healthcare affected 190 million records, disrupting operations.
✅ Stock Market Reaction → UNH shares plummeted 16% in a single day, marking their lowest level in nearly five years.
🔹 Future Outlook
Despite setbacks, UNH remains a dominant player in healthcare, with over 50 million insured members. Analysts believe the company can recover under Hemsley’s leadership, but short-term volatility remains high.
United Health Group (UNH) trading at 250$ 0.618 F5 Support ( Golden Ratio )
Anticipating buyers to come in at this level.
XLV. The Health Care Select Sector SPDR Fund (XLV) is an exchange-traded fund (ETF) that tracks the healthcare sector within the S&P 500. It includes companies from pharmaceuticals, biotechnology, healthcare equipment, and healthcare services.
This sector is trading near Weekly Support Nodes
Weekly OP + Weekly F3 nodes
or Weekly OP F3 Agreement
Its also Oversold.
ELV - Elevance Health Inc, one of the main competitors to UNH in this space
trading at Weekly F3 Support ( 0.382 retracement ) + Weekly Oversold
Given UNH, ELV and the broader sector, XLV, are all trading at important Higher Timeframe Support nodes...
with UNH down 20% today at one point, and down 38.2% from its highs ( largely within a month )
Looking for a Technical Bounce against Higher Timeframe Support nodes, on UNH, and the sector.
"Will we see a bounce at these levels? Drop your thoughts below!"
- Joseph AuXano
#UNH #XLV #HealthcareStocks #TradingView
5/15/25 - $unh - I'll comment.5/15/25 :: VROCKSTAR :: NYSE:UNH
I'll comment.
- as a rule, i typically avoid companies that have credible issues associated with frauds. we all know UNH committed some pretty heinous crimes against humanity
- institutions that want to buy this thing at $250 are probably getting massive pushback from their risk teams today and being told "fine don't sell as much" (even tho they r going to be forced to trim), but no add.
- so any bid here comes from a headline (real or fake). add to this you have 5/16 opex tmr, this ticker isn't an insignificant mcap and so index and flows work against it at the mgn. furthermore, any statement forthcoming perhaps doesn't hit until next week? i mean... the mgmt team is running or getting *squashed*. lawyers r not going to push for immediate statements here bc *muh stock price*
- options chain pretty solid around $250. stock probably doesn't have a ton left to go here.
- IFFFFFF i were to trade this long, i'd probably wait for an abysmal close. and a red open. and i'd punt on some call spreads next week. let's see. but given NXT and GAMB today that r keeping me busy... i have zero interest to complicate my life.
idk if that helps but i've gotten a lot of DMs
oh on valuation... there's no "E" we can stand on here. so realistically this could easily trade at single digit PE on re-rated expectations which is another 25% lower... keep that in mind. this won't be a V shaped recovery trade. so timing/ and paying VERY close attention is what's required to get an edge/ make risk-adj. $. just not my cup of tea.
oh - and F the crooks here. we all know u r guilty.
V
unh knife catchI won't do anything with this, it's more for fun. Long term this could be a good buying opportunity. Usually Dow stocks respect monthly/quarterly levels. So if you're a dividend investor and willing to hold longer term, this could be a nice area.
Where does the tumble stop for $UNHUNH has been in a free fall been absolute chaos for..reasons.
I see a possible Shark. Sharks can complete at the 886 or the 113. This happens to be around the 236 and 382 of the Macro fib retracement. We also have the 200 Monthly SMA.
So where does it stop tumbling? The 236, the 382 or the 200 Monthly SMA? I am betting it goes to the 236 and bounces sometime around earnings. Notice that trendline that goes back to 1998 that acts as support. I am betting it bounces around where the trendline and 236 intersect sometime around the next earnings. That's a good spot to go long.
UnitedHealth Group faces DOJ criminal probeUnitedHealth Group faces DOJ criminal probe amid stock turmoil. Will the gaps be filled? (and most importantly when)
This situation shows the critical importance of compliance and transparency in the healthcare industry, especially for companies managing public funds.
UnitedHealth Group is under a criminal investigation by the U.S. Department of Justice for potential Medicare fraud, as reported by the Wall Street Journal. This follows a civil inquiry earlier this year and a separate Senate investigation into the company's Medicare billing practices.
The company's stock has experienced significant volatility, recently closing at $308.01, marking a 48% decline over the past month and a 40% drop year-over-year. Analysts have adjusted their outlooks accordingly, with Oppenheimer setting a price target of $400, KeyBanc at $450, and B of A Securities at $350.
#trading #tradingcards #tradingstrategy #daytrading #swingtrading #stocktrading #optionstrading
Now what do you do with UNH ?For me, it is a screaming buy. Hear me out.
This was in my watch list for a while but I never get a chance to go long as the price keeps climbing up or my funds were tied up with other shares/ETFs, etc.
A 50% fall from the peak but what is more important is the parabolic move down, almost 5 straight weeks of 90 degrees plunge down. The sell down seems pretty serious and by any metric you used, it is way oversold and begs for a reversal.
However, on the daily chart, it is still RED which means the selling is not done yet and we could probably see more sell down days ahead to 196-279 price level.
So, I will be watching it closely this time and be ready to nibble some when it falls further.
Healthcare stocks seem to be battered in this sector rotation round so get ready your ammunition , the reversal could come sooner than later........
UNH and DOJ. What has ever happened? Value stock Back with another freebie for the followers. I am not getting enough love after the freebies and multibaggers I have thrown at the community.
UNH. Investigations, fraud, malpractices.
Does that change the fact that it is the biggest health insurer in the USA? People reading this might be insured with UNH.
What have investigations ever brought the USA?
A slap on the wrist, a fine and some low key employee fired. Does that change your insurance? Does that wipe out 100+ billion from UNH balance sheet? NO
A value stock for a value investor.
The Foxx announces a position of 10000 stocks of UNH @284.1 post market 19:35 on May 14 2025. Happy to average down till it goes to 1. That is conviction. Bill ackman who?
Follow the Foxx, throw some love in the comments, and ill maybe throw another bone for yall soon..
UnitedHealth UNH - Institutional Exit or Long-Term Opportunity?Key Insights
UNH has witnessed a historic -24% monthly drop, breaking multiple key long-term supports on extreme volume — often a sign of institutional distribution or capitulation.
Bearish Outlook (Primary Bias):
Current price is testing the 0.5 Fibonacci retracement ($322 - $287), a critical make-or-break zone.
A monthly close below $287 will likely trigger the next leg lower toward $250 and possibly the $200 psychological handle.
The bearish momentum remains dominant, confirmed by RSI deep in bear territory and MACD accelerating down.
Invalidation Levels (For Shorts):
Aggressive short invalidation: Weekly close above $395.33.
Full bearish invalidation (shift to bullish bias): Monthly close above $447.21.
Bullish Opportunity Zones:
Watch for strong bullish reversal at the $287 - $249 support zone, aligning with 0.382 Fib and historical demand.
If $200 - $160 is ever reached, it becomes a high-probability accumulation zone for long-term investors.
Probability:
$395 - $447 Strong Short Bias , Look for retests & rejection
$322 - $287 Neutral to Bearish (watch reaction), Currently testing key support
$249 - $200 High-Probability Long Setup, Look for confirmation reversal
Above $447.21 Bullish Bias Resumes, Invalidate bears, shift to longs
Conclusion:
UNH is at a critical long-term support crossroad.
Patience is key—traders should avoid chasing the lows and wait for higher-probability setups at key levels.
Let the chart guide the trade
UNH next strong Support $286As of May 13, 2025, UnitedHealth Group (UNH) stock is experiencing significant volatility due to recent corporate developments:
📉 Current Stock Performance
Price: Around $337.02 in premarket trading, down approximately 11% 1.
Previous Close: $380.72 2.
📰 Key News
CEO Change: Andrew Witty has resigned as CEO for personal reasons. Stephen Hemsley, former CEO (2006–2017), has returned to the role.
2025 Guidance Suspended: UnitedHealth has suspended its 2025 financial outlook due to higher-than-expected Medicare Advantage costs and increased care activity 1.
📊 Analyst Outlook
Consensus Rating: Moderate Buy based on 24 analyst ratings.
Average Price Target: $596.86, suggesting a potential 56.77% upside from the previous close 2.
Price Target Range: $490 to $700.
Would you like a chart of UNH’s recent stock performance or a breakdown of analyst ratings over time?
